AY4, an agonistic anti-death receptor 4 MAB, induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 283-291

  Lee, Bok Soon ^a,b   Cha, Hyun Young ^a,b   Shin, Yoo Seob ^a,b   Kim, Yong Sung ^b,c   Kim, Chul Ho ^a,b  

^a Department of Otolaryngology ^*  (South Korea)

^b Kangwon National University College of Medicine   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Agonistic antibody; Anaplastic thyroid carcinoma (ATC); Apoptosis; Death receptor 4; ROS

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AY4; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE;

AGONISTIC ANTIBODY; ANAPLASTIC THYROID CARCINOMA (ATC); APOPTOSIS; DEATH RECEPTOR 4; ROS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; THYROID NEOPLASMS;

EID: 84879465467     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0405     Document Type: Article

References (21)

1. Ain KB, Egorin MJ & DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10 587-594. (doi:10.1089/thy.2000.10.587)
2. Ashkenazi A 2002 Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nature Reviews. Cancer 2 420-430. (doi:10.1038/nrc821)
3. Ashkenazi A & Herbst RS 2008 To kill a tumor cell: the potential of proapoptotic receptor agonists. Journal of Clinical Investigation 118 1979-1990. (doi:10.1172/JCI34359)
4. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L & Fusco A 2010 Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29 105-116. (doi:10.1038/onc.2009.306)
5. Chao DT, Linette GP, Boise LH, White LS, Thompson CB & Korsmeyer SJ 1995 Bcl-XL and Bcl-2 repress a common pathway of cell death. Journal of Experimental Medicine 182 821-828. (doi:10.1084/jem.182.3.821)
6. Chen SY, Lu FJ, Gau RJ, Yang ML & Huang TS 2002 15-Deoxy-delta12,14- prostaglandin J2 induces apoptosis of a thyroid papillary cancer cell line (CG3 cells) through increasing intracellular iron and oxidative stress. Anti-cancer Drugs 13 759-765. (doi:10.1097/00001813-200208000-00011)
7. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G et al. 2007 Proteasome inhibitors synergize with tumor necrosis factor-related apoptosisinduced ligand to induce anaplastic thyroid carcinoma cell death. Journal of Clinical Endocrinology and Metabolism 92 1938-1942. (doi:10.1210/jc.2006-2157)
8. Du ZX, Zhang HY, Meng X, Guan Y & Wang HQ 2009 Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 9 56. (doi:10.1186/1471-2407-9-56)
9. Festa M, Petrella A, Alfano S & Parente L 2009 R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. International Journal of Cancer 124 2728-2736. (doi:10.1002/ijc.24260)
10. Finkel T 2003 Oxidant signals and oxidative stress. Current Opinion in Cell Biology 15 247-254. (doi:10.1016/S0955-0674(03)00002-4)
11. Huang Z 2000 Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19 6627-6631. (doi:10.1038/sj.onc.1204087)
12. Kelekar A & Thompson CB 1998 Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends in Cell Biology 8 324-330. (doi:10.1016/S0962- 8924(98)01321-X)
13. Lee BS, Kang SU, Hwang HS, Kim YS, Sung ES, Shin YS, Lim YC & Kim CH 2012 An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Letters 322 45-57. (doi:10.1016/j.canlet.2012.02.007)
14. Liu ZM, Li L, Zhu XY & Song FZ 2009 Molecular mechanism of apoptosis induced by PsL5F in human anaplastic thyroid carcinoma FRO cells. Sichuan Da Xue Xue Bao Yi Xue Ban 40 1015-1020.
15. Liu XH, Chen GG, Vlantis AC, Tse GM & van Hasselt CA 2010 Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. Molecular and Cellular Endocrinology 320 128-135. (doi:10.1016/j.mce.2010.02.004)
16. Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS, Fesik SW, Fill M & Thompson CB 1999 Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO Journal 18 632-643. (doi:10.1093/emboj/18.3.632)
17. Petrella A, Ercolino SF, Festa M, Gentilella A, Tosco A, Conzen SD & Parente L 2006 Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. European Journal of Cancer 42 3287-3293. (doi:10.1016/j.ejca.2006.07.018)
18. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G & De Maria R 2003 Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Research 63 6784-6790.
19. Sung ES, Park KJ, Lee SH, Jang YS, Park SK, Park YH, Kwag WJ, Kwon MH & Kim YS 2009 A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular Cancer Therapeutics 8 2276-2285. (doi:10.1158/1535-7163.MCT-09-0235)
20. Sung ES, Kim A, Park JS, Chung J, Kwon MH & Kim YS 2010 Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 15 1256-1269. (doi:10.1007/s10495-010-0521-9)
21. Veness MJ, Porter GS & Morgan GJ 2004 Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ Journal of Surgery 74 559-562. (doi:10.1111/j.1445-2197.2004.03062.x)